Treatment of multiple myeloma with recombinant alpha-interferon.
Treatment of multiple myeloma with recombinant alpha-interferon.
复制标题
用重组α-干扰素治疗多发性骨髓瘤。
作者：
J. Quesada;R. Alexanian;Misha C. Hawkins;B. Barlogie;E. Borden;L. Itri;J. Gutterman
32例多发性骨髓瘤患者每日肌肉注射重组α-干扰素克隆A（rIFN α A），初始剂量为12 × 10（6）U/m2。在27例可评价缓解的患者中，14例既往未治疗的患者中有7例（50%）和13例既往化疗复发或失败的患者中有2例（15%）获得了肿瘤缓解。在所有有肿瘤反应的患者中，血清免疫球蛋白从低于正常水平恢复，这是化疗中很少观察到的效果。肿瘤缓解的中位持续时间超过14个月（范围，6 - 20）。中度至重度疲劳是主要的副作用，需要所有患者降低剂量。我们的结论是，治疗早期阶段的多发性骨髓瘤与rIFN α A是有益的，因为大量的反应率和改善血清免疫球蛋白的合成。rIFN α A与其他药物联合治疗多发性骨髓瘤具有潜在的作用。
Thirty-two patients with multiple myeloma were treated with recombinant alpha-interferon clone A (rIFN alpha A) daily by intramuscular injection with an initial dose of 12 X 10(6) U/m2. Of 27 patients evaluable for response, tumor responses were obtained in seven of 14 previously untreated patients (50%) and two of 13 who had relapsed or failed prior chemotherapy (15%). In all patients who had tumor response, there was restoration from subnormal levels of serum immunoglobulins, an effect infrequently observed with chemotherapy. The median duration of tumor responses exceeded 14 months (range, 6 to 20). Moderate-to-severe fatigue was the predominant side effect and necessitated dose reductions in all patients. We conclude that treatment of early stages of multiple myeloma with rIFN alpha A is beneficial because of the substantial response rate and the improvement in the synthesis of serum immunoglobulins. rIFN alpha A has a potential role in combination with other agents in the treatment of multiple myeloma.